30 closest matches · ranked by relevance
ATTR-CM
Primary: Number of Participants According to Clinical Diagnosis Predicted Using the Machine Learning (ML) Algorithm — 203; 133; 35; 187 Participants
Amyloidosis · Amyloid Cardiomyopathy · Transthyretin Amyloidosis
Primary: A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT…
Autism
Primary: Primary Outcome Measurements to Determine Efficacy of Treatment With CM-AT Versus Placebo for Changes in the Aberrant Behavior Checklist Subscale for Irritability /…
Dilated Cardiomyopathy
Primary: Aortic Velocity Time Integral (VTI) — 22.4; 21.7; 19.4; 18.1 cm
Symptomatic Transthyretin Amyloid Cardiomyopathy
Primary: Part A: Change From Baseline To Month 12 Of Treatment In Distance Walked During The Six-minute Walk Test (6MWT) — -3.86 meters
Transthyretin Amyloid Cardiomyopathy
Primary: Number of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs) — 45; 21; 17; 6 Participants
Asthma
Primary: Asthma Control Test (ACT) — 21.8; 19.9 units on a scale
Transthyretin (TTR) Amyloid Cardiomyopathy
Primary: Number of Participants With Adverse Drug Reactions — 45; 7 Participants
Thoracic Diseases
Primary: Number of Subjects With Procedural Technical Success — 123 Participants
Trauma, Brain · Brain Injuries · Traumatic Brain Injury
Primary: Change in Buss-Perry Aggression Questionnaire Score — -1.7; -5.91; -8.51 score on a scale
Myocardial Infarction · Heart Failure · Heart Valve Diseases
Primary: Number of CR Sessions Completed Within 6 Months in Patients Randomized to HYCR vs. Patients Randomized to Traditional CBCR (Usual Care). — 28.7; 27.6 Number of cardiac…
Transthyretin Gene Mutations · Transthyretin Amyloidosis
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 621; 175; 66; 4 Participants
Locally Advanced Non-Small Cell Lung Cancer
Primary: Number of Dose Limiting Toxicities in Patients Taking Atovaquone in Combination With Radical Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer. — 0; 0; 0; 2…
Post-traumatic Stress Disorder · Alcohol Abuse · Alcohol Dependence
Primary: Number of Patients With High Levels of Adolescent PTSD Symptoms — 9; 12; 11; 12 Participants — p=0.71
Heart Failure With Left Bundle Branch Block
Primary: Combined Endpoint of All-cause Mortality and Intervention for Heart Failure Decompensation — 430; 470 Participants — p=0.077
High Cholesterol
Primary: Overall Correct Initial TASS Outcome, Worst Case Imputation, First Co-Primary Endpoint (Self-Selection Population) — 1085 Participants
Acute Promyelocytic Leukemia
Primary: Complete Response (CR) Rate — 55; 5; 15 Participants
Hereditary Transthyretin Amyloidosis (ATTRv) · Polyneuropathy
Primary: Change in Neuropathy Impairment Score (NIS) at Month 12 for ATTRv — 1.6 Change in score*months
Heart Failure, Congestive
Primary: Unplanned Hospital Admissions for Cardiac Reasons OR Death of Cardiovascular Causes OR Progression to Chronic Atrial Fibrillation — 43; 44 participants
Teamwork · Implementation
Primary: Change in Teamwork Knowledge From Baseline to 3-month Follow-up — 75.60; 74.72; 80.00; 75.00 percentage correct answers — p=.03
Alcohol Use Disorder
Primary: Biochemically Measured Change in Alcohol Abstinence. — 347; 615; 209 Number of negative BAC samples by phase.
Cardiac Amyloidosis
Primary: Rate of Cardiac Amyloidosis Diagnosis — 24 Participants
Depressive Disorder, Major · Bipolar Disorder · Schizo Affective Disorder
Primary: Acceptance of Intervention-Number of Participants Who Dropped Out of Treatment — 4; 3 Participants
Atrial Fibrillation
Primary: Number of Participants With Cardiovascular Hospitalization and AF-related Emergency Department Visits — 118; 130 Participants
Adenoid Cystic Carcinoma
Primary: Best Overall Response Rate — 0; 0; 11; 5 Participants
Tachycardia, Ventricular · Ventricular Fibrillation
Primary: Efficacy of Anti Tachycardia Pacing (ATP) Therapy (Burst, 8 Pulses, 88 %, 1 Sequence) to Terminate All Types of Ventricular Tachycardia. — 64.7; 68.2 Percent of VT…
Transthyretin Amyloidosis
Primary: Median of Uptake of Evuzamitide as Measured by Volume of Interest in Milliliters — 78.7; 253.6; 177.2; 39.6 mL
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Primary: Change From Baseline at Month 12 in Six-Minute Walk Test (6-MWT) — -21.345; -8.150 meters — p=0.0162
Atrial Fibrillation
Primary: Number of Participants With Acute Success — 53 Participants
Cerebral Cavernous Malformation
Primary: Percent Change in Mean Lesional QSM (QSM Change Score) — 7.35; 0.24; 15.18; 26.80 absolute value of percent change